Gossamer Bio released today the topline results from the Phase 3 PROSERA clinical study evaluating seralutinib, an investigational inhaled therapy, in people living with pulmonary arterial hypertension (PAH). Gossamer Bio and Chiesi are jointly developing seralutinib under a global collaboration agreement.
 

Please click here to read Gossamer’s press release. 
 

Chiesi is working with Gossamer Bio to review the full dataset for PAH and finalize the next steps. 
 

Chiesi would like to thank all patients, investigators and clinical teams involved in the PROSERA study for their commitment and collaboration throughout the programme. Their dedication and contribution were essential to the conduct of this global clinical study.